Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Amortizatization of Intangibles (2019 - 2025)

Theravance Biopharma (TBPH) has disclosed Amortizatization of Intangibles for 8 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Amortizatization of Intangibles fell 11.25% to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 9.81% decrease, with the full-year FY2024 number at $4.4 million, up 6.31% from a year prior.
  • Amortizatization of Intangibles was $1.0 million for Q3 2025 at Theravance Biopharma, up from $940000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $1.7 million in Q4 2022 to a low of $341000.0 in Q1 2022.
  • A 5-year average of $1.0 million and a median of $1.0 million in 2025 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: crashed 54.1% in 2022, then soared 202.35% in 2023.
  • Theravance Biopharma's Amortizatization of Intangibles stood at $743000.0 in 2021, then skyrocketed by 129.48% to $1.7 million in 2022, then tumbled by 39.53% to $1.0 million in 2023, then increased by 2.13% to $1.1 million in 2024, then dropped by 4.84% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Amortizatization of Intangibles are $1.0 million (Q3 2025), $940000.0 (Q2 2025), and $966000.0 (Q1 2025).